Fenbendazole is a broad-spectrum benzimidazole anthelmintic commonly used in veterinary medicine to treat parasitic infections in animals. In recent years, it has drawn attention for its potential applications in human medicine, although research remains limited and preliminary. One area of interest is its possible anticancer properties. Laboratory studies suggest thatFenbendazole 500 mg may disrupt microtubule formation, interfere with glucose metabolism, and induce apoptosis in certain cancer cells, mechanisms somewhat similar to established chemotherapeutic agents. These findings have prompted experimental exploration of its role as an adjunct therapy in cancer treatment.
Beyond oncology, fenbendazole’s antiparasitic activity may offer benefits for neglected tropical diseases in humans, especially those caused by helminths. Since it is effective against a wide range of intestinal parasites in animals, researchers are considering whether it could be adapted for safe human use where current treatments are limited. Additionally, early evidence indicates that fenbendazole may modulate immune responses, potentially offering benefit in conditions where immune regulation plays a role.
Despite these promising signals, it is important to emphasize that fenbendazole is not yet approved for human use. Clinical trials are necessary to evaluate its safety, dosage, and effectiveness before it can be recommended in medical practice. Self-medication is strongly discouraged.